PL358918A1 - Enancjomer 1,2-skondensowanej chinoliny hamujący transferazę farnezylową - Google Patents

Enancjomer 1,2-skondensowanej chinoliny hamujący transferazę farnezylową

Info

Publication number
PL358918A1
PL358918A1 PL01358918A PL35891801A PL358918A1 PL 358918 A1 PL358918 A1 PL 358918A1 PL 01358918 A PL01358918 A PL 01358918A PL 35891801 A PL35891801 A PL 35891801A PL 358918 A1 PL358918 A1 PL 358918A1
Authority
PL
Poland
Prior art keywords
farnesyl transferase
transferase inhibiting
quinoline enantiomer
annelated quinoline
annelated
Prior art date
Application number
PL01358918A
Other languages
English (en)
Other versions
PL209521B1 (pl
Inventor
Marc Gaston Venet
Patrick Rene Angibaud
David William End
Original Assignee
Janssen Pharmaceutica N.V.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Pharmaceutica N.V. filed Critical Janssen Pharmaceutica N.V.
Publication of PL358918A1 publication Critical patent/PL358918A1/pl
Publication of PL209521B1 publication Critical patent/PL209521B1/pl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains three hetero rings
    • C07D487/14—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/10—Anti-acne agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Pulmonology (AREA)
  • Dermatology (AREA)
  • Immunology (AREA)
  • Rheumatology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Pain & Pain Management (AREA)
  • Surgery (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
PL358918A 2000-06-22 2001-06-13 Kompozycja farmaceutyczna, sposób jej wytwarzania i zastosowanie PL209521B1 (pl)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP00202181 2000-06-22
PCT/EP2001/006747 WO2001098302A1 (en) 2000-06-22 2001-06-13 Farnesyl transferase inhibiting 1,2-annelated quinoline enantiomer

Publications (2)

Publication Number Publication Date
PL358918A1 true PL358918A1 (pl) 2004-08-23
PL209521B1 PL209521B1 (pl) 2011-09-30

Family

ID=8171675

Family Applications (1)

Application Number Title Priority Date Filing Date
PL358918A PL209521B1 (pl) 2000-06-22 2001-06-13 Kompozycja farmaceutyczna, sposób jej wytwarzania i zastosowanie

Country Status (33)

Country Link
US (3) US20030114471A1 (pl)
EP (1) EP1296984B1 (pl)
JP (1) JP4919575B2 (pl)
KR (2) KR100846370B1 (pl)
CN (1) CN1207296C (pl)
AR (1) AR030704A1 (pl)
AT (1) ATE294804T1 (pl)
AU (3) AU6396201A (pl)
BG (1) BG65894B1 (pl)
BR (1) BRPI0111743B8 (pl)
CA (1) CA2410232C (pl)
CZ (1) CZ295278B6 (pl)
DE (1) DE60110592T2 (pl)
EA (1) EA005065B1 (pl)
EE (1) EE04966B1 (pl)
EG (1) EG24180A (pl)
ES (1) ES2241830T3 (pl)
HR (1) HRP20020989B1 (pl)
HU (1) HU229095B1 (pl)
IL (2) IL153560A0 (pl)
IS (1) IS2596B (pl)
JO (1) JO2361B1 (pl)
MX (1) MXPA02012845A (pl)
MY (1) MY127734A (pl)
NO (1) NO324494B1 (pl)
NZ (1) NZ522481A (pl)
PA (1) PA8519501A1 (pl)
PL (1) PL209521B1 (pl)
SA (1) SA01220349B1 (pl)
SK (1) SK285699B6 (pl)
UA (1) UA73572C2 (pl)
WO (1) WO2001098302A1 (pl)
ZA (1) ZA200210305B (pl)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003018135A1 (en) * 2001-08-24 2003-03-06 Wyeth Holdings Corporation Method of using 5-(arylsulfonyl)-,5-(arylsulfinyl), and 5-(arylsulfanyl)-thiazolidine-2,4-diones for inhibition of farnesyl-protein transferase
ATE336496T1 (de) 2002-04-15 2006-09-15 Janssen Pharmaceutica Nv Farnesyl transferase hemmende tricyclische quinazolinederivate substitutiert mit kohlenstoff-gebundenen imidazolen oder triazolen
US20050003422A1 (en) 2003-07-01 2005-01-06 Mitch Reponi Methods for assessing and treating cancer
US10076512B2 (en) 2014-05-01 2018-09-18 Eiger Biopharmaceuticals, Inc. Treatment of hepatitis delta virus infection
US11311519B2 (en) 2014-05-01 2022-04-26 Eiger Biopharmaceuticals, Inc. Treatment of hepatitis delta virus infection
US20180338993A1 (en) * 2014-12-04 2018-11-29 Eiger Biopharmaceuticals, Inc. Treatment of hepatitis delta virus infection
WO2016172342A1 (en) 2015-04-21 2016-10-27 Eiger Biopharmaceuticals, Inc. Pharmaceutical compositions comprising lonafarnib and ritonavir
SMT202100712T1 (it) 2015-08-17 2022-01-10 Kura Oncology Inc Metodi di trattamento di pazienti di cancro con inibitori di farnesil trasferasi
TW201818965A (zh) 2016-11-03 2018-06-01 美商庫拉腫瘤技術股份有限公司 以法呢基轉移酶（ｆａｒｎｅｓｙｌ ｔｒａｎｓｆｅｒａｓｅ）抑制劑治療癌症病患之方法

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1519765A (en) * 1974-09-05 1978-08-02 Ici Ltd Pesticidal dihydrotetrazolo(1,5a) quinazolines compositions and processes
US4141979A (en) * 1976-12-23 1979-02-27 Pfizer Inc. Tetrazolo[a]quinazol-5-ones antiallergy and antiulcer agents
GB9513577D0 (en) * 1995-07-04 1995-09-06 Brotherwood Rodney J Improvements in passenger carrying vehicles
TW349948B (en) * 1995-10-31 1999-01-11 Janssen Pharmaceutica Nv Farnesyl transferase inhibiting 2-quinolone derivatives
SK283335B6 (sk) * 1995-12-08 2003-06-03 Janssen Pharmaceutica N. V. (Imidazol-5-yl)metyl-2-chinolinónové deriváty, spôsob a medziprodukty na ich prípravu, ich použitie a farmaceutické kompozície na ich báze
WO1997036876A1 (en) 1996-04-03 1997-10-09 Merck & Co., Inc. Inhibitors of farnesyl-protein transferase
TW591030B (en) * 1997-03-10 2004-06-11 Janssen Pharmaceutica Nv Farnesyl transferase inhibiting 1,8-annelated quinolinone derivatives substituted with N- or C-linked imidazoles
RU2205831C2 (ru) * 1997-04-25 2003-06-10 Янссен Фармацевтика Н.В. Хиназолиноны, ингибирующие фарнезилтрансферазу
AU740603B2 (en) 1997-06-02 2001-11-08 Janssen Pharmaceutica N.V. (imidazol-5-yl)methyl-2-quinolinone derivatives as inhibitors of smooth muscle cell proliferation
ID26987A (id) * 1998-07-06 2001-02-22 Janssen Pharmaceutica Nv Inhibitor-inhibitor transferase protein farnesil dengan sifat-sifat peka terhadap sinar radiasi in vivo
HRP20000904A2 (en) 1998-07-06 2001-12-31 Janssen Pharmaceutica Nv Farnesyl protein transferase inhibitors for treating arthropathies
ES2237125T3 (es) * 1998-08-27 2005-07-16 Pfizer Products Inc. Derivados de quinolin-2-ona utiles como agentes anticancerigenos.
ID27562A (id) * 1998-08-27 2001-04-12 Pfizer Prod Inc Turunan-turunan kinolin-2-ona tersubstitusi alkunil yang berguna sebagai zat anti kanker
ID29241A (id) * 1998-12-23 2001-08-16 Janssen Pharmaceutica Nv Turunan-turunan kinolin teranelasi-1,2
US6462201B1 (en) * 1998-12-29 2002-10-08 Isp Investments Inc. Process for the production of N-vinyl-2-pyrrolidone by vinylation
PL349839A1 (en) * 1999-02-11 2002-09-23 Pfizer Prod Inc Heteroaryl-substituted quinolin-2-one derivatives useful as anticancer agents
HN2000000266A (es) 2000-01-21 2001-05-21 Pfizer Prod Inc Compuesto anticanceroso y metodo de separacion de enantiomeros util para sintetizar dicho compuesto.
US6838467B2 (en) * 2000-02-24 2005-01-04 Janssen Pharmaceutica N. V. Dosing regimen
WO2002024686A2 (en) 2000-09-25 2002-03-28 Janssen Pharmaceutica N.V. Farnesyl transferase inhibiting 6-heterocyclylmethyl quinoline and quinazoline derivatives
US7067531B2 (en) 2000-09-25 2006-06-27 Angibaud Patrick Rene Farnesyl transferase inhibiting 6-heterocyclylmethyl quinolinone derivatives

Also Published As

Publication number Publication date
SK285699B6 (sk) 2007-06-07
PL209521B1 (pl) 2011-09-30
US20080114009A1 (en) 2008-05-15
HUP0300872A2 (hu) 2003-07-28
CA2410232C (en) 2008-10-07
EA200300048A1 (ru) 2003-04-24
EE04966B1 (et) 2008-02-15
HU229095B1 (en) 2013-07-29
DE60110592T2 (de) 2006-01-19
US20030114471A1 (en) 2003-06-19
IL153560A0 (en) 2003-07-06
IS6590A (is) 2002-10-25
AU2006220405A1 (en) 2006-10-12
NO324494B1 (no) 2007-10-29
BRPI0111743B1 (pt) 2019-03-26
KR20030009463A (ko) 2003-01-29
WO2001098302A1 (en) 2001-12-27
AU2001263962B2 (en) 2006-07-20
NZ522481A (en) 2004-09-24
SK502003A3 (en) 2003-05-02
BR0111743A (pt) 2003-07-08
NO20026032L (no) 2002-12-16
EG24180A (en) 2008-09-28
UA73572C2 (en) 2005-08-15
AU6396201A (en) 2002-01-02
EA005065B1 (ru) 2004-10-28
DE60110592D1 (de) 2005-06-09
JP2004501153A (ja) 2004-01-15
EP1296984A1 (en) 2003-04-02
CZ295278B6 (cs) 2005-06-15
MY127734A (en) 2006-12-29
NO20026032D0 (no) 2002-12-16
BRPI0111743B8 (pt) 2021-05-25
MXPA02012845A (es) 2003-05-15
BG65894B1 (bg) 2010-04-30
IS2596B (is) 2010-03-15
IL153560A (en) 2011-06-30
JP4919575B2 (ja) 2012-04-18
HRP20020989A2 (en) 2005-02-28
BG107310A (bg) 2003-07-31
CZ2003114A3 (cs) 2003-05-14
HUP0300872A3 (en) 2004-11-29
EP1296984B1 (en) 2005-05-04
HK1058363A1 (en) 2004-05-14
AR030704A1 (es) 2003-09-03
ES2241830T3 (es) 2005-11-01
PA8519501A1 (es) 2002-08-29
JO2361B1 (en) 2006-12-12
CA2410232A1 (en) 2001-12-27
AU2006220405B2 (en) 2009-05-21
ZA200210305B (en) 2004-03-19
US8329714B2 (en) 2012-12-11
KR100846370B1 (ko) 2008-07-15
KR20070121847A (ko) 2007-12-27
CN1437601A (zh) 2003-08-20
HRP20020989B1 (hr) 2011-05-31
EE200200695A (et) 2004-06-15
KR100831940B1 (ko) 2008-05-23
CN1207296C (zh) 2005-06-22
US8318753B2 (en) 2012-11-27
ATE294804T1 (de) 2005-05-15
US20070259902A1 (en) 2007-11-08
SA01220349B1 (ar) 2007-01-23

Similar Documents

Publication Publication Date Title
TNSN03144A1 (en) Pyrrolopyrimidines as protein kinase inhibitors
GEP20053688B (en) Substituted-Triazolopyrimidines as Anticancer Agents
NZ517758A (en) Pyrazolopyrimidines useful as therapeutic agents
MY142019A (en) Pyrazolo-quinazoline derivatives, process for their preparation and their use as kinase inhibitors
GEP20053595B (en) Cyclopentanoindoles, Compositions Containing Such Compounds and Methods of Treatment
MY117961A (en) Inhibitors of farnesyl protein transferase
MY141739A (en) Substituted quinazoline derivatives as inhibitors of aurora kinases
GEP20053479B (en) Pyrrolo[2,3-d]Pyrimidine Compounds, Pharmaceutical Composition Containing the Same and Use
AP2003002929A0 (en) Pyrrolopyrimidines as protein kinase inhibitors
PL377821A1 (pl) 2,4,6-tripodstawione pirymidyny jako inhibitory kinazy fosfatydyloinozytolu (PI) 3 i ich zastosowanie w leczeniu nowotworu
MY145332A (en) Trisubstituted 4-aminopyrazolopyrimidines as cyclin dependent kinase inhibitors
IL173348A (en) Thienopyridine compounds, pharmaceuticals containing them and their use in the preparation of drugs
MY139072A (en) Pyrrolo[3,4-c]pyrazole derivatives active as kinase inhibitors, process for their preparation and pharmaceutical compositions comprising them
YU4903A (sh) N-/5-///5-alkil-2-oksazolil/metil/tio/-2-tiazolil/ karboksamidni inhibitori ciklin zavisnih kinaza
EG24180A (en) Farnesyl transferase inhibiting 1,2-annelated quinoline enantiomer
AU2972701A (en) 3-aminopyrazole inhibitors of cyclin dependent kinases
DE50211929D1 (en) Pyrimidinderivate
WO2001030331A3 (en) Therapeutic compositions including protein kinase c inhibitors
WO2000052134A3 (en) Inhibitors of prenyl-protein transferase
WO2000001415A3 (en) Use of inhibitors of protein kinase c epsilon to treat pain
MXPA04005809A (es) Inhibidores de proteinas quinasas.
WO2001060458A3 (en) Inhibitors of prenyl-protein transferase
TW200503683A (en) Methods of using and compositions comprising immunomodulatory compounds for treatment, modification and management of pain
MY122477A (en) Sertraline oral concentrate
WO2002076930A3 (en) Substituted diarylureas as stimulators for fas-mediated apoptosis